New use of metals as nanosized radioenhancers

Anticancer Research

Volumn 34, Issue 1, 2014, Pages 443-453

  Pottier, Agnès ^a   Borghi, Elsa ^a   Levy, Laurent ^a  

^a NANOBIOTIX   (France)

Author keywords

Functionalized hafnium oxide; Local cancer treatment; Metals; Nanoparticle radioenhancer; Review

Indexed keywords

ANTINEOPLASTIC AGENT; CISPLATIN; DNA; GOLD; HAFNIUM; HAFNIUM OXIDE; METAL COMPLEX; METAL OXIDE; NANOPARTICLE; NANOSPHERE; NBTXR3 NANOPARTICLE; RADIOISOTOPE; RUTHENIUM; UNCLASSIFIED DRUG; METAL; METAL NANOPARTICLE; RADIOSENSITIZING AGENT;

ADVANCED CANCER; CANCER CELL; CANCER CELL DESTRUCTION; CANCER THERAPY; CELL DEATH; CLINICAL RESEARCH; CONFERENCE PAPER; DNA ADDUCT; DNA DAMAGE; DRUG EFFICACY; DRUG HALF LIFE; DRUG POTENCY; DRUG STRUCTURE; HEAD AND NECK CANCER; HEALTH CARE; HUMAN; IONIZING RADIATION; NONHUMAN; PARTICLE SIZE; PHYSICAL CHEMISTRY; RADIATION ABSORPTION; RADIATION DOSE; RADIOSENSITIVITY; RADIOTHERAPY; RISK BENEFIT ANALYSIS; SOFT TISSUE SARCOMA; SURFACE CHARGE; THERMODYNAMICS; TUMOR CELL; FUNCTIONALIZED HAFNIUM OXIDE; LOCAL CANCER TREATMENT; NANOPARTICLE RADIOENHANCER; NEOPLASM; PROGNOSIS; REVIEW;

FUNCTIONALIZED HAFNIUM OXIDE; LOCAL CANCER TREATMENT; METALS; NANOPARTICLE RADIOENHANCER; REVIEW;

ANTINEOPLASTIC AGENTS; HUMANS; METAL NANOPARTICLES; NEOPLASMS; PROGNOSIS; RADIATION-SENSITIZING AGENTS;

EID: 84897020561     PISSN: 02507005     EISSN: 17917530     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (90)

1. Norman CC and James MB: Clinical radiosensitization: Why it does and does not work. J Clin Oncol 17: 1-3, 1999.
2. Begg AC, Stewart FA and Vens C: Strategies to improve radiotherapy with targeted drugs. Nat Rev Cancer 11: 239-253, 2011.
3. Wilson WR and Hay MP: Targeting hypoxia in cancer therapy. Nat Rev Cancer 1: 393-410, 2011.
4. Ryan JL: Ionizing radiation: The good, the bad, and the ugly. J Invest Dermatol 132: 985-993, 2012.
5. Valdes G and Iwamoto KS: Re-evaluation of cellular radiosensitization by 5-fluorouracil: High-dose, pulsed administration is effective and preferable to conventional low-dose, chronic administration. Int J Radiat Biol 2013 89: 851-862, 2013.
6. Ghotra VP, Geldof AA and Danen EH: Targeted radiosensitization in prostate cancer. Curr Pharm Des 19: 2819-2828, 2013.
7. Prasanna PG, Stone HB, Wong RS, Capala J, Bernhard EJ, Vikram B and Coleman CN: Normal tissue protection for improving radiotherapy: Where are the Gaps? Transl Cancer Res 1: 35-48, 2012.
8. Tepper JE and Wang AZ: Improving local control in rectal cancer: Radiation sensitizers or radiation dose? J Clin Oncol 28: 1623-1624, 2010.
9. Yazbeck VY, Villaruz L, Haley M and Socinski MA: Management of normal tissue toxicity associated with chemoradiation (primary skin, esophagus, and lung). Cancer J 19: 231-237, 2013.
10. Matuschek C, Bölke E, Belka C, Ganswindt U, Henke M, Stegmaier P, Bamberg M, Welz S, Debus J, Gioules A, Voigt A, Volk G, Ohmann C, Wiegel T, Budach V, Stuschke M, Schipper J, Gerber PA and Budach W: Feasibility of 6-month maintenance cetuximab after adjuvant concurrent chemoradiation plus cetuximab in squamous cell carcinoma of the head and neck. Strahlenther Onkol 189: 625-631, 2013.
11. Lee TS, Kang SB, Kim YT, Park BJ, Kim YM, Lee JM, Kim SM, Kim YT, Kim JH and Kim KT: Chemoradiation with paclitaxel and carboplatin in high-risk cervical cancer patients after radical hysterectomy: A Korean Gynecologic Oncology Group study. Int J Radiat Oncol Biol Phys 86: 304-10, 2013.
12. Lawrence YR, Paulus R, Langer C, Werner-Wasik M, Buyyounouski MK, Komaki R, Machtay M, Smith C, Axelrod RS, Wasserman T, Bradley JD and Movsas B: The addition of amifostine to carboplatin and paclitaxel based chemoradiation in locally advanced non-small cell lung cancer: Long-term followup of Radiation Therapy Oncology Group (RTOG) randomized trial 9801. Lung Cancer 80: 298-305, 2013.
13. De Caluwé L, Van Nieuwenhove Y and Ceelen WP: Preoperative chemoradiation versus radiation alone for stage II and III resectable rectal cancer. Cochrane Database Syst Rev 2:CD006041, 2013.
14. Anticancer Res 32: 2487-2499, 2012.
15. Sensitization of Cancer Cells for Chemo/Immuno/Radio-therapy. Benjamin Bonavida, Editor, In: Cancer Drug Discovery and Development, Beverly A. Teicher, Series Editor, 2008.
16. Linkous AG and Yazlovitskaya EM: Novel radiosensitizing anticancer therapeutics.
17. Faiz M. Khan: Modern radiation therapy, chapter 19 part III. In: The Physics of Radiation Therapy, Lippincott, Williams & Wilkins, Fourth Edition, Baltimore, 2010.
18. Committee on State of the Science of Nuclear Medicine: Advancing Nuclear Medicine Through Innovation. The National Academies Press, 2007.
19. Wang J, Byrne JD, Napier ME and DeSimone JM: More effective nanomedicines through particle design. Small 7: 1919-1931, 2011.
20. Nel AE, Mädler L, Velegol D, Xia T, Hoek EM, Somasundaran P, Laessig F, Castranova V and Thompson M: Understanding biophysicochemical interactions at the nano-bio interface. Nat Mater 8: 543-557, 2009.
21. Mahon E, Salvati A, Bombelli FB, Lynch I and Dawson KA: Designing the nanoparticle-biomolecule interface for targeting and therapeutic delivery. J Control Release 161: 164-174, 2012.
22. Walczyk D, Bombelli FB, Monopoli MP, Lynch I and Dawson KA: What the cell "sees" in bionanoscience. J Am Chem Soc 132: 5761-5768, 2010.
23. Kim JA, A˚berg C, Salvati A and Dawson KA: Role of cell cycle on the cellular uptake and dilution of nanoparticles in a cell population. Nat Nanotechnol 7: 62-68, 2011.
24. McMahon SJ, Hyland WB, Muir MF, Coulter JA, Jain S, Butterworth KT, Schettino G, Dickson GR, Hounsell AR, O'Sullivan JM, Prise KM, Hirst DG and Currell FJ: Nanodosimetric effects of gold nanoparticles in megavoltage radiation therapy. Radiother Oncol 100: 412-416, 2011.
25. Douglass M, Bezak E and Penfold S: Monte Carlo investigation of the increased radiation deposition due to gold nanoparticles using kilovoltage and megavoltage photons in a 3D randomized cell model. Med Phys 40: 071710, 2013.
26. Maggiorella L, Barouch G, devaux C, Pottier A, Deutsch E, Bourhis J, Borghi E and Levy L: Nanoscale radiotherapy with hafnium oxide nanoparticles. Future Oncol 8: 1167-1181, 2012.
27. Leung MK, Chow JC, Chithrani BD, Lee MJ, Oms B and Jaffray DA: Irradiation of gold nanoparticles by x-rays: Monte Carlo simulation of dose enhancements and the spatial properties of the secondary electrons production. Med Phys 38: 624-631, 2011.
28. McMahon SJ, Hyland WB, Muir MF, Coulter JA, Jain S, Butterworth KT, Schettino G, Dickson GR, Hounsell AR, O'Sullivan JM, Prise KM, Hirst DG and Currell FJ: Biological consequences of nanoscale energy deposition near irradiated heavy atom nanoparticles. Sci Rep 1: 18, 2011.
29. Jones BL, Krishnan S and Cho SH: Estimation of microscopic dose enhancement factor around gold nanoparticles by Monte Carlo calculations. Med Phys 37: 3809-3816, 2010.
30. Cho SH: Estimation of tumour dose enhancement due to gold nanoparticles during typical radiation treatments: A preliminary Monte Carlo study. Phys Med Biol 50: N163-N173, 2005.
31. Komeda S and Casini A: Next generation anticancer metallodrugs. Curr Top Med Chem 12: 219-235, 2012.
32. Barry NPE and Sadler PJ: Exploration of the medical periodic table: Towards new targets. Chem Commun 49: 5106-5131, 2013.
33. Gasser G, Ott I and Metzler-Nolte N: Organometallic anticancer compounds. J Med Chem 54: 3-25, 2011.
34. Jungwirth U, Kowol CR, Keppler BK, Hartinger CG, Berger W and Heffeter P: Anticancer activity of metal complexes: Involvement of redox processes. Antioxid Redox Signal 15: 1085-1127, 2011.
35. Rezaee M, Hunting DJ and Sanche L: New insights into the mechanism underlying the synergistic action of ionizing radiation with platinum chemotherapeutic drugs: The role of low-energy electrons. Int J Radiat Oncol Biol Phys S0360-3016(13)02744-2, 2013.
36. Sancho-Martinez SM, Prieto-Garcia L, Prieto M, Lopez-Novoa JM and Lopez-Hernandez FJ: Subcellular targets of cisplatin cytotoxicity: An integrated view. Pharmacol Ther 136: 35-55, 2012.
37. Kartalou M and Essigmann JM: Mechanism of resistance to cisplatin. Mut Res 478: 23-43, 2001.
38. Sadowitz P, Hubbard BA, Dabrowiak JC, Goodisman J, Tacka KA, Aktas MK, Cunningham MJ, Dubowy RL and Souid A-K: Kinetics of cisplatin binding to cellular DNA and modulations by thiol-blocking agents and thiol drugs. Drug Metab Dispos 30: 183-190, 2002.
39. Meijer C, Mulder NH, Hospers GAP, Uges DRA and de Vries EGE: The role of glutathione in resistance to cisplatin in a human small cell lung cancer cell line. Br J Cancer 62: 72-77, 1990.
40. Andrews PA, Murphy MP and Howell SB: Metallothionein-mediated cisplatin resistance in human ovarian carcinoma cells. Cancer Chemother Pharmacol 19: 149-154, 1987.
41. Di Pasqua AJ, Goodisman J and Dabrowiak JC: Understanding how the platinum anticancer drug carboplatin works: From the bottle to the cell. Inorg Chim Acta 389: 29-35, 2012.
42. Faivre S, Chan D, Salinas R, Woynarowska B and Woynarowski JM: DNA strand breaks and apoptosis induced by oxaliplatin in cancer cells. Biochem Pharmacol 66: 225-237, 2003.
43. Chaney SG, Campbell SL, Bassett E and Wu Y: Recognition and processing of cisplatin- and oxaliplatin DNA adducts. Crit Rev Oncol Hematol 53: 3-11, 2005.
44. Hall MD and Hambley TW: Platinum(IV) antitumor compounds: Their bioinorganic chemistry. Coord Chem Rev 232: 49-67, 2002.
45. Schilder RJ, LaCreta FP, Perez RP, Johnson SW, Brennan JM, Rogatko A, Nash S, McAleer C, Hamilton TC, Roby D, Young RC, Ozols RF and O'Dwyer PJ: Phase I and pharmacokinetic study of ormaplatin (tetraplatin, NSC 363812) administered on a day 1 and day 8 schedule. Cancer Res 54: 709-717, 1994.
46. Ott I: On the medicinal chemistry of gold complexes as anticancer drugs. Coord Chem Rev 256: 1670-1681, 2009.
47. Deponte M, Urig S, Arscott LD, Fritz-Wolf K, Réau R, Herold- Mende C, Koncarevic S, Meyer M, Davioud-Charvet E, Ballous DP, Williams CH and Becker K: Mechanistic studies on a novel, highly potent gold-phosphole inhibitor of human glutathione reductase. J Biol Chem 280: 20628-20637, 2005.
48. Shaw CF: Gold-based therapeutic agents. Chem Rev 99: 2589-2600, 1999.
49. Rademaker-Lakhai JM, van den Bongard D, Pluim D, Beijnen JH and Schellens JHM: A Phase I and pharmacological study with imidazolium-trans-DMSO-imidazole-tetrachlororuthenate, a novel ruthenium anticancer agent. Clin Cancer Res 10: 3717-3727, 2004.
50. Hartinger CG, Zorbas-Seifried S, Jakupec MA, Kynast B, Zorbas H and Keppler BK: From bench to bedside - preclinical and early clinical development of the anticancer agent indazolium trans-[tetrachlorobis(1H-indazole)ruthenate(III)] (KP1019 or FFC14A). J Inorg Biochem 100: 891-904, 2006.
51. 2]- complexes, where L=imidazole, 1,2,4-triazole, indazole. Inorg Chem 43: 7083-7093, 2004.
52. Novakova O, Chen H, Vrana O, Rodger A, Sadler PJ and Brabec V: DNA interactions of monofunctional organometallic ruthenium(II) antitumor complexes in cell-free media. Biochemistry 42: 11544-11554, 2003.
53. Morris RE, Aird RE, Murdoch P del S, Chen H, Cummings J, Hughes ND, Parsons S, Parkin A, Boyd G, Jodrell DI and Sadler PJ: Inhibition of cancer cell growth by ruthenium(II) arene complexes. J Med Chem 44: 3616-3621, 2001.
54. 2(pta)]. J Inorg Biochem 102: 1743-1748, 2008.
55. Kassis AI and Adelstein SJ: Radiobiologic principles in radionuclide therapy. J Nucl Med 46: 4S-12S, 2005.
56. Baidoo KE, Yong K and Brechbiel MW: Molecular pathways: Targeted α-particle radiation therapy. Clin Cancer Res 19: 530-537, 2013.
57. Imam SK: Advancements in cancer therapy with alpha-emitters: A review. Int J Radiat Oncol Biol Phys 51: 271-278, 2001.
58. 211At-labeled monoclonal antibodies. Nucl Med Biol 34: 779-785, 2007.
59. Friesen C, Roscher M, Hormann I, Leib O, Marx S, Moreno J and Miltner E: Anti-CD33-antibodies labelled with the alpha-emitter bismuth-213 kill CD-33-positive acute myeloid leukaemia cells specifically by activation of caspases and break radio-and chemoresistance by inhibition of the anti-apoptotic proteins X-linked inhibitor of apoptosis protein and B-cell lymphoma-extra large. Eur J Cancer 49: 2542-2554, 2013.
60. Nilsson S, Franzén L, Parker C, Tyrrell C, Blom R, Tennvall J, Lennernäs B, Petersson U, Johannessen DC, Sokal M, Pigott K, Yachnin J, Garkavij M, Strang P, Harmenberg J, Bolstad B and Bruland OS: Bone-targeted radium-223 in symptomatic, hormone-refractory prostate cancer: A randomised, multicentre, placebo-controlled phase II study. Lancet Oncol 8: 587-594, 2007.
61. Otte A, Mueller-Brand J, Dellas S, Nitzsche EU, Herrmann R and Maecke HR: Yttrium-90-labelled somatostatin-analogue for cancer treatment. Lancet 351: 417-418, 1998.
62. Goffredo V, Paradiso A, Ranieri G and Gadaleta CD: Yttrium-90 (90Y) in the principal radionuclide therapies: An efficacy correlation between peptide receptor radionuclide therapy, radioimmunotherapy and transarterial radioembolization therapy. Ten years of experience (1999-2009). Crit Rev Oncol Hematol 80: 393-410, 2011.
63. McEwan AJB: Use of radionuclides for the palliation of bone metastases. Semin Radiat Oncol 110: 103-114, 2000.
64. Rutar FJ, Augustine SC, Kaminski MS, Wahl RL, Siegel JA and Colcher S: Feasibility and safety of outpatient Bexxar® therapy (tositumomab and iodine I 131 tositumomab) for non-Hodgkin's lymphoma based on radiation doses to family members. Clin Lymphoma 2: 164-172, 2001.
65. Wang Y, Tao H, Yi X, Wang Z and Wang M: Clinical significance of zoledronic acid and strontium-89 in patients with asymptomatic bone metastases from non-small cell lung cancer. Clin Lung Cancer 14: 254-260, 2013.
66. Lee BQ, Kibédi T, Stuchbery AE and Robertson KA: Atomic radiation in the decay of medical radioisotopes: A physics perspective. Comput Math Methods Med 2012: 651475, 2012.
67. Morgenroth A, Dinger C, Zlatopolskiy BD, Al-Momani E, Glatting G, Mottaghy FM and Reske SN: Auger electron emitter against multiple myeloma-targeted endo-radio therapy with 125I-labeled thymidine analogue 5-iodo-4-thio-2-deoxyuridine. Nucl Med Biol 38: 1067-1077, 2011.
68. Weeks AJ, Blower PJ and Lloyd DR: p53-Dependant radiobiological responses to internalised Indium-111 in human cells. Nucl Med Biol 40: 73-79, 2013.
69. Etheridge ML, Campbell SA, Erdman AG, Haynes CL, Wolf SM and McCullough J: The big picture on nanomedicine: The state of investigational and approved nanomedicine products. Nanomedicine 9: 1-14, 2013.
70. Boisseau P and Loubaton B: Nanomedicine, nanotechnology in medicine. Comptes Rendus Physique 12: 620-636, 2011.
71. Jolivet JP and Barron AR: Nanomaterials fabrication. In: Environmental Nanotechnology Applications and Impacts of Nano-materials. Wiesner MR and Bottero JY (eds.). New York: MacGrawHill, 2007.
72. Wang Z and Cuschieri A: Tumour cell labelling by magnetic nanoparticles with determination of intracellular iron content and spatial distribution of the intracellular iron. Int J Mol Sci 14: 9111-9125, 2013.
73. Papa A-L, Basu S, Sengupta P, Banerjee D, Sengupta S and Harfouche R: Mechanistic studies of Gemcitabine-loaded nanoplatforms in resistant pancreatic cancer cells. BMC Cancer 12: 419-430, 2012.
74. Astolfo A, Schültke E, Menk RH, Kirch RD, Juurlink BHJ, Hall C, Harsan L-A, Stebel M, Barbetta D, Tromba G and Arfelli F: In vivo visualization of gold-loaded cells in mice using x-ray computed tomography. Nanomedicine 9: 284-292, 2013.
75. Roeske JC, Nunez L, Hoggarth M, Labay E and Weichselbaum RR: Characterization of the theoretical radiation dose enhancement from nanoparticles. Technol Cancer Res Treat 6: 385-401, 2007.
76. Auffan M, Rose J, Wiesner MR, Bottero J-Y: Chemical stability of metallic nanoparticles: A parameter controlling their cellular toxicity in vitro. Environ Pollut 157: 1127-1133, 2009.
77. Lim Z-Z J, Li J-E J, NG C-T, Yung L-Y L and Bay B-H: Gold nanoparticles in cancer therapy. Acta Pharmacol Sin 32: 983-990, 2011.
78. Hainfeld JF, Slatkin DN, Focella TM and Smilowitz HM: Gold nanoparticles: A new X-ray contrast agent. Br J Radiol 79: 248-253, 2006.
79. Powell AC, Paciotti GF and Libutti SK: Colloidal gold: A novel nanoparticle for targeted cancer therapeutics. Methods Mol Biol 624: 375-384, 2010.
80. Day ES, Zhang L, Thompson PA, Zawaski JA, Kaffes CC, Gaber MW, Blaney SM and West JL: Vascular-targeted photothermal therapy of an orthotopic murine glioma model. Nanomedicine 7: 1133-1148, 2012.
81. Chattopadhyay N, Cai Z, Kwon YL, Lechtman E, Pignol JP and Reilly RM: Molecularly targeted gold nanoparticles enhance the radiation response of breast cancer cells and tumor xenografts to X-radiation. Breast Cancer Res Treat 137: 81-91, 2013.
82. Hainfeld JF, Slatkin DN and Smilowitz HM: The use of gold nanoparticles to enhance radiotherapy in mice. Phys Med Biol 49: N309-N315, 2004.
83. Chithrani DB, Jelveh S, Jalali F, van Prooijen M, Allen C, Bristow RG, Hill RP and Jaffray DA: Gold nanoparticles as radiation sensitizers in cancer therapy. Radiat Res 173: 719-728, 2010.
84. Chen YS, Hung YC, Liau I and Huang GS: Assessment of the in vivo toxicity of gold nanoparticles. Nanoscale Res Lett 4: 858-864, 2009.
85. Sadauska E, Danscher G, Toltenberg M, Vogel U, Larsen A and Wallin H: Protracted elimination of gold nanoparticles from mouse liver. Nanomedicine 5: 162-169, 2009.
86. Cho WS, Cho M, Jeong J, Choi M, Cho HY, Han BS, Kim SH, Kim HO, Lim YT, Chung BH and Jeong J: Acute toxicity and pharmacokinetics of 13 nm-sized PEG-coated gold nanoparticles. Toxicol Appl Pharmacol 236: 16-24, 2009.
87. Sengupta J, Datta P, Patra HK, Dasgupta AK and Gomes A: In vivo interaction of gold nanoparticles after acute and chronic exposures in experimental animal models. J Nanosci Nanotechnol 13: 1660-70, 2013.
88. Jolivet JP, Cassaignon S, Chanéac C, Chiche D, Durupthy O and Portehault D: Design of metal oxide nanoparticles: Control of size, shape, crystalline structure and functionalization by aqueous chemistry. Comptes Rendus Chimie 13: 40-51, 2010.
89. Maier-Hauff K, Ulrich F, Nestler D, Niehoff H, Wust P, Thiesen B, Orawa H, Budach V and Jordan A: Efficacy and safety of intratumoral thermotherapy using magnetic iron-oxide nanoparticles combined with external beam radiotherapy on patients with recurrent glioblastoma multiforme. J Neurooncol. 103: 317-24, 2011.
90. Bradbury MS, Phillips E, Montero PH, Cheal SM, Stambuk H, Durack JC, Sofocleous CT, Meester RJ, Wiesner U and Patel S: Clinically translated silica nanoparticles as dual-modality cancer-targeted probes for image-guided surgery and interventions. Integr Biol 5: 74-86, 2013.